Last reviewed · How we verify
NCT04374851
A Comparative Clinical Investigation of Two Hearing Instrument Digital Signal Processing
NA trial testing Polaris miniRITE BTE in Hearing Loss in 19 participants. Completed in 30 November 2020.
30 November 2020
Quick facts
| Lead sponsor | Bernafon AG |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 19 |
| Start date | 3 August 2020 |
| Primary completion | 30 November 2020 |
| Estimated completion | 30 November 2020 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Polaris miniRITE BTE
- Viron miniRiTE BTE
Conditions studied
- Hearing Loss — all drugs for Hearing Loss →
Sponsor
Bernafon AG
Who can join
18 and older, any sex, with Hearing Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to show that the performance of the new digital signal processing system is better than the system used in the currently CE marked devices. Speech in narrowband noise and acceptable levels of noise should be improved with the new system, and speech understanding overall should not be negatively affected. There should be no artefacts or unwanted noises caused by the new system.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04374851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hearing Loss
Currently open trials in the same condition.
- NCT07176936 — Improving Speech in Noise Using Noninvasive Stimulation · NA · recruiting
- NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
- NCT07218913 — Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III · Phase 1 · recruiting
- NCT07414329 — Efficacy and Effectiveness of an Investigational Behind-the-Ear Hearing Device Kit · NA · recruiting
- NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting
Other Bernafon AG trials
Trials by the same sponsor.
- NCT04939259 — A Comparative Clinical Investigation of Musician's Preference With Hearing Aids · NA · completed
- NCT04147442 — A Standard Music Program Compared to an Optimized Music Program · NA · completed
- NCT04146272 — A Comparison of a New Acoustic Feedback Canceller in Hearing Aids With the Current System · NA · completed
- NCT04168229 — A Clinical Investigation of the Benefit: BTE Hearing Aids Versus ITE Hearing Aids · NA · completed
- NCT03498274 — A Comparison of a Currently Marketed Hearing Aid Programmed With Two Different Fitting Methods · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04374851 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bernafon AG
- Last refreshed: 7 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04374851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing